In vitro assessment of edoxaban anticoagulant effect in pediatric plasma

Anticoagulant therapy in pediatric patients remains an issue and safer therapies, such as direct oral anticoagulants could overcome the limitations of conventional anticoagulant treatments in this population. Edoxaban, a factor Xa inhibitor, is used for the prevention and treatment of venous thrombo...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2019-06, Vol.178, p.112-118
Main Authors: Sinegre, Thomas, Zlobecki, Mélissa, Doré, Eric, Pereira, Bruno, Grèze, Victoria, Lebreton, Aurélien
Format: Article
Language:English
Subjects:
Adolescent
Anticoagulants - pharmacology
Anticoagulants - therapeutic use
Child
Child, Preschool
Coagulation
Edoxaban
Factor Xa Inhibitors - pharmacology
Factor Xa Inhibitors - therapeutic use
Female
Human health and pathology
Humans
Infant
Life Sciences
Male
Pediatric
Pediatrics
Plasma - drug effects
Pyridines - pharmacology
Pyridines - therapeutic use
Thiazoles - pharmacology
Thiazoles - therapeutic use
Thrombin generation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anticoagulant therapy in pediatric patients remains an issue and safer therapies, such as direct oral anticoagulants could overcome the limitations of conventional anticoagulant treatments in this population. Edoxaban, a factor Xa inhibitor, is used for the prevention and treatment of venous thromboembolism. Due to its pharmacokinetic characteristics, edoxaban is a promising candidate molecule for children. This study compared edoxaban in vitro effect in children and adults. Blood samples were prospectively collected from 87 adults and 97 children (n = 12:
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2019.04.014